Feb 13, 2024   SOURCE: PR NewsWire

Protein Inhibitors Global Market Report 2024 - A $125 Billion Market in 2028, Registering Compound Annual Growth of 9%

DUBLIN, Feb. 13, 2024 /PRNewswire/ -- The "Protein Inhibitors Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

In 2023, North America emerged as the largest region in the protein inhibitors market while sectors like oncology and inflammatory diseases continue to climb at an accelerated pace globally. Technological advancements and increased focus on precision medicine have opened up numerous opportunities in this niche market.

The publication's compilation of market data underscores the sector's projected expansion from $80.99 billion in 2023 to an impressive $125.26 billion by 2028. Notably, a compound annual growth rate (CAGR) of 9.0% is expected, driven predominantly by the accelerating prevalence of chronic diseases and the surge in personalized medicine.

Industry Dynamics and Key Growth Factors

Advancements in the field have been marked by a noticeable increase in regulatory approvals and significant steps towards the development of treatments with heightened efficacy and reduced adverse effects. This convergence of drug development advancements and regulatory success is contributing substantially to market growth.

Emerging trends indicate an increasing popularity of precision medicine, which tailors treatments to the genetic profile of individuals. Protein inhibitors are central to this approach, especially in the battle against complex diseases, such as various cancers and autoimmune disorders.

Strategic Developments and Market Influencers

Stakeholders within the protein inhibitors landscape are engaging in strategic partnerships and acquisitions, aiming to broaden their product offerings and fortify market presence. One of the report highlights includes the strategic collaboration between major industry players to co-develop innovative treatments targeting a range of diseases.

Research has also depicted a budding interest in the development of novel inhibitors, such as TYK2 inhibitors, which demonstrate significant potential for autoimmune conditions treatment.

Key Players and Product Offerings

    --  Leading companies in the protein inhibitors sector are continuously
        innovating and enhancing their portfolios, offering a diverse range of
        products that address various health issues.
    --  The industry consists of prominent names that specialize in producing
        sophisticated protein kinase inhibitors and monoclonal antibodies, among
        other compounds, all having broad applications across different medical
        specialties.

Market research emphasizes the importance of distribution through various channels including hospital pharmacies, independent pharmacies, and online platforms to ensure patient accessibility to these crucial treatments.

The comprehensive report provides in-depth analysis and projections for stakeholders, researchers, and market observers, offering invaluable insights into this dynamically evolving market.

Key Markets Covered:

    --  By Product: Protein Kinase Inhibitors; Monoclonal Antibody; Other
        Products
    --  By Application: Oncology; Inflammatory Diseases; Other Applications
    --  By Distribution Channel: Hospital Pharmacies; Independent Pharmacies;
        Online Pharmacies

Companies Profiled

    --  Bayer
    --  AstraZeneca plc
    --  F. Hoffmann-La Roche Ltd.
    --  Teva Pharmaceutical Industries Ltd.
    --  Apotex Inc.
    --  Novartis International AG
    --  GlaxoSmithKline plc
    --  Pfizer Inc.
    --  Boehringer Ingelheim International GmbH
    --  Abbott Laboratories
    --  Amgen Inc.
    --  Baxter International Inc.
    --  Merck & Co. Inc.
    --  Interprotein Corporation
    --  AbbVie Inc.
    --  Bristol Myers Squibb Company
    --  Galapagos NV
    --  Priovant Therapeutics Inc.
    --  Tempus Labs Inc.
    --  ReCode Therapeutics Inc.
    --  Satellite Bio Inc.
    --  Ambagon Therapeutics Inc.
    --  Biogen Inc.
    --  Eli Lilly and Company
    --  Gilead Sciences Inc.
    --  Johnson & Johnson
    --  Regeneron Pharmaceuticals Inc.
    --  Sanofi S.A.
    --  Takeda Pharmaceutical Company Limited
    --  Vertex Pharmaceuticals Inc.
    --  Lonza Group AG
    --  Catalent Inc.
    --  Thermo Fisher Scientific Inc.
    --  Charles River Laboratories International Inc.
    --  WuXi AppTec Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/bfklyt

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg



View original content:https://www.prnewswire.com/news-releases/protein-inhibitors-global-market-report-2024---a-125-billion-market-in-2028-registering-compound-annual-growth-of-9-302060922.html

SOURCE Research and Markets